BioXcel Therapeutics stock rating reiterated at Buy by H.C. Wainwright
PositiveFinancial Markets

BioXcel Therapeutics has received a positive endorsement from H.C. Wainwright, which has reiterated its 'Buy' rating on the company's stock. This is significant as it reflects confidence in BioXcel's potential for growth and success in the biopharmaceutical sector, suggesting that investors may see promising returns.
— Curated by the World Pulse Now AI Editorial System